- Stocks
- Healthcare
- NASDAQ: BEAM

Price (delayed)

$30.39

Market cap

$2.2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.13

Enterprise value

$2.14B

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a

The EPS is up by 28% year-on-year and by 8% since the previous quarter

The net income has increased by 22% year-on-year and by 8% since the previous quarter

BEAM's gross profit is down by 34% since the previous quarter but it is up by 18% year-on-year

Beam Therapeutics's revenue has decreased by 34% from the previous quarter but it has increased by 18% YoY

The debt has grown by 23% YoY

What are the main financial stats of BEAM

Market
Valuations
Earnings

Shares outstanding

72.4M

Market cap

$2.2B

Enterprise value

$2.14B

Price to earnings (P/E)

N/A

Price to book (P/B)

2.92

Price to sales (P/S)

34.93

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

35.07

Revenue

$60.92M

EBIT

-$285.68M

EBITDA

-$271.53M

Free cash flow

-$26.42M

Per share
Balance sheet
Liquidity

EPS

-$4.13

Free cash flow per share

-$0.38

Book value per share

$10.41

Revenue per share

$0.87

TBVPS

$19.16

Total assets

$1.34B

Total liabilities

$608.24M

Debt

$182.01M

Equity

$733.47M

Working capital

$869.3M

Debt to equity

0.25

Current ratio

4.89

Quick ratio

4.88

Net debt/EBITDA

0.23

Margins
Efficiency
Dividend

EBITDA margin

-445.7%

Gross margin

100%

Net margin

-474.5%

Operating margin

-555.6%

Return on assets

-20.8%

Return on equity

-37.6%

Return on invested capital

-26.2%

Return on capital employed

-25.5%

Return on sales

-468.9%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Beam Therapeutics stock price performed over time

Intraday

0.16%

1 week

-8.52%

1 month

-21.92%

1 year

-48.21%

YTD

-22.3%

QTD

-22.3%

How have Beam Therapeutics's revenue and profit performed over time

Revenue

$60.92M

Gross profit

$60.92M

Operating income

-$338.48M

Net income

-$289.09M

Gross margin

100%

Net margin

-474.5%

Beam Therapeutics's operating margin has shrunk by 63% QoQ but it has increased by 27% YoY

The net margin has contracted by 38% from the previous quarter but it has grown by 34% YoY

BEAM's gross profit is down by 34% since the previous quarter but it is up by 18% year-on-year

Beam Therapeutics's revenue has decreased by 34% from the previous quarter but it has increased by 18% YoY

What is Beam Therapeutics's growth rate over time

What is Beam Therapeutics stock price valuation

P/E

N/A

P/B

2.92

P/S

34.93

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

35.07

The EPS is up by 28% year-on-year and by 8% since the previous quarter

The price to book (P/B) is 30% lower than the last 4 quarters average of 4.2

BEAM's equity is down by 11% year-on-year but it is up by 2.7% since the previous quarter

Beam Therapeutics's revenue has decreased by 34% from the previous quarter but it has increased by 18% YoY

BEAM's price to sales (P/S) is 23% lower than its last 4 quarters average of 45.5

How efficient is Beam Therapeutics business performance

BEAM's ROIC has soared by 52% YoY and by 14% QoQ

The company's return on assets rose by 41% YoY and by 6% QoQ

The return on sales has declined by 38% since the previous quarter but it is up by 34% year-on-year

The ROE has increased by 33% YoY and by 6% QoQ

What is BEAM's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BEAM.

How did Beam Therapeutics financials performed over time

The total assets is 121% more than the total liabilities

BEAM's quick ratio is down by 19% year-on-year but it is up by 5% since the previous quarter

BEAM's current ratio is down by 18% YoY but it is up by 5% QoQ

The debt is 75% less than the equity

The company's debt to equity rose by 39% YoY

The debt has grown by 23% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.